Hot Investor Mandate: Asia-Based Life Science Venture Capital Investing in Pre-A to Series B Therapeutics, Devices, and Diagnostics Companies Across Global Markets

August 4, 2026 ~ Next Phase Admin ~ Leave a comment

This investment firm is headquartered in Asia with offices in North America and focuses on early-stage investments in life sciences and healthcare. The firm typically participates in pre-Series A to Series B financing rounds, with initial investment sizes ranging from several hundred thousand dollars to several million dollars and the potential for follow-on investments. The firm seeks opportunities primarily in Europe, as well as North America and the United Kingdom. The firm is open to both leading and co-investing in financing rounds.

The firm is interested in therapeutics, medical devices, and diagnostics. The firm is open to evaluating digital health and AI-related companies but has limited investment activity in these areas to date. The firm takes an opportunistic approach across subsectors and indications, with areas of interest including immunology, immuno-oncology, central nervous system disorders, and kidney-related diseases.

For therapeutics, the firm considers opportunities from Phase I and beyond, particularly companies with proof-of-concept data or clinical validation supporting their technologies. For medical devices and diagnostics, the firm generally seeks more mature companies with products or prototypes in development, along with clear regulatory approval strategies.

The firm does not have specific requirements for management teams but prefers to work with founding teams that have prior entrepreneurial experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Mandate: US-Based Family Office Investing in Therapeutics, Medical Devices, and Diagnostics Companies with Strong Social Impact Focus Addressing Underserved Medical Needs

August 4, 2026 ~ Next Phase Admin ~ Leave a comment

This single-family office represents private family interests in the United States. The firm is flexible in terms of investment size but generally looks to invest at least several hundred thousand dollars per round, depending on round size and anticipated capital requirements. The firm prefers Series A and later-stage companies, while pre-Series A opportunities are considered depending on technology maturity. Currently, the firm invests primarily in companies based in North America.

The firm seeks breakthrough technologies with a strong social impact focus in the therapeutics, medical devices, and diagnostics sectors that address underserved medical needs or provide innovative and disruptive approaches to existing medical procedures and treatments. Areas of particular interest include optical and sound-based technologies, devices that reduce reliance on drug-based treatments, orthopedics, gene and nucleic acid-based therapies, immuno-oncology, and technologies addressing sensory loss.

The firm reviews co-investment opportunities in private companies and, on an opportunistic basis, may consider investments in micro- and small-cap public companies as a direct investor. The firm seeks companies that have completed seed financing and have reached key intellectual property milestones, including allowance of claims by relevant patent authorities.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Mandate: US-Based Healthcare VC Focused on Medical Technologies and Digital Health Solutions, Investing Across Early- and Late-Stage Opportunities

August 4, 2026 ~ Next Phase Admin ~ Leave a comment

This venture capital firm was founded in the mid-2000s and manages approximately $100 million in assets across multiple funds. The firm makes equity investments ranging from several hundred thousand dollars to several million dollars, with additional capital reserved for follow-on rounds. The firm invests in companies located throughout North America and Europe and plans to make several new investments over the next year. The firm invests in both early-stage companies and later-stage commercial growth opportunities.

The firm focuses on companies developing medical devices, diagnostics, and healthcare IT products, with an emphasis on capital-efficient technologies that can reach the market quickly and reduce the cost of delivering quality healthcare. The firm is open to a broad range of subsectors and indications within medical technology, with particular interest in technologies related to cardiovascular health and neurological applications.

The firm seeks companies with skilled and experienced management teams. The firm generally looks to take board seats in portfolio companies after investment and plays an active role in supporting company growth and strategic decisions.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Mandate: CVC Arm of Global Pharmaceutical Company Focuses on Early-Stage Therapeutics and Technologies Enhancing Drug Discovery and Pharmaceutical R&D

August 4, 2026 ~ Next Phase Admin ~ Leave a comment

This corporate venture fund was established in 2023 to invest in innovative life sciences companies developing technologies strategically aligned with its parent pharmaceutical company’s long-term research and development priorities. Headquartered in the United States, the fund manages evergreen capital and invests globally, with a primary focus on companies based in North America, Europe, and Asia. The fund typically makes initial investments of several million dollars and has the capacity to provide additional follow-on capital over the life of a portfolio company. The fund seeks to support breakthrough scientific innovation while building long-term strategic relationships with emerging biotechnology companies through minority equity investments.

The fund focuses on early-stage therapeutics, enabling platform technologies, and digital technologies that can enhance drug discovery and pharmaceutical R&D. Areas of particular interest include advanced therapeutic modalities, targeted drug discovery approaches, next-generation biologics, RNA-based technologies, and platform technologies capable of generating multiple therapeutic programs across diverse disease areas. Within digital technologies, the fund primarily seeks artificial intelligence, machine learning, computational biology, and data science applications that improve target identification, drug design, lead optimization, and other aspects of drug discovery and development. The fund focuses primarily on preclinical and early clinical-stage opportunities and does not invest in medical devices, diagnostics, healthcare services, or patient-centric digital health applications.

The fund invests in privately held biotechnology companies and does not maintain rigid management team requirements. The fund typically participates as a minority investor alongside other life sciences investors and generally does not lead financing rounds or require board representation. Instead, the fund seeks collaborative relationships with innovative companies whose technologies have strategic relevance to its research organization while allowing portfolio companies to remain operationally independent.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Establish Your Innovation Hub at RESI JPM 2027

August 4, 2026 ~ Next Phase Admin ~ Leave a comment

By Max Braht, VP of Business Development, LSN

Every January, JPM Healthcare Week transforms San Francisco into the global center of the life science industry, bringing together investors, pharmaceutical executives, biotech leaders, and innovators from around the world. For organizations looking to showcase their regional ecosystem, portfolio companies, or innovation network, RESI JPM 2027 offers a unique opportunity to establish a visible and strategic presence during one of the industry’s most influential weeks.

Located within the San Francisco Marriott Marquis, RESI JPM is the premier partnering conference dedicated to early-stage life science companies. The event connects startups with active investors, strategic partners, and business development professionals through curated partnering meetings, educational programming, and networking opportunities.

Life Science Nation invites regional organizations, innovation hubs, accelerators, and industry partners to create their own branded Innovation Hub alongside RESI JPM. These flexible hosting opportunities allow organizations to provide a central gathering place for their ecosystem while taking advantage of the high concentration of attendees already participating in RESI and JPM Healthcare Week.

RESI JPM 2027 Venue: Salons 9–15 (Yerba Buena Ballroom, Lower B2 Level) with total space exceeding 17,000 sq ft.

Organizations can kick off the week with a private networking reception on Sunday, welcoming investors, founders, corporate partners, and key stakeholders before the week’s meetings begin. During RESI JPM on Monday and Tuesday, dedicated salon spaces adjacent to the conference offer an ideal location for hosting meetings, showcasing portfolio companies, conducting presentations, and serving as a home base for delegates throughout the event.

Tech/Innovation hubs also benefit from prominent branding within the RESI environment and the opportunity for their startup cohorts to engage directly in RESI’s partnering platform, creating additional exposure and meeting opportunities with investors and strategic partners.

Whether representing a regional life science cluster, government agency, incubator, accelerator, or investment organization, establishing an Innovation Hub at RESI JPM positions your organization at the center of the world’s largest life science partnering week while providing lasting value for your innovation ecosystem.

To learn more about creating an Innovation Hub at RESI JPM 2027, contact Life Science Nation at salescore@lifesciencenation.com.

Meet the First Believers: The Investors Behind Tomorrow’s Breakthrough Companies

August 4, 2026 ~ Next Phase Admin ~ Leave a comment

By Momo Yamamoto, Senior Investor Research Analyst, LSN

Every successful life science company has a defining moment in its fundraising journey. Long before a major venture capital round or strategic partnership, there is often an investor willing to take the very first leap of faith.

At 9:00 AM on Wednesday, September 23, Day 2 of RESI Boston 2026 begins with one of the conference’s most valuable discussions for early-stage founders: The First Believers: The Investors Behind Tomorrow’s Breakthrough Companies.

Securing that first investment is about much more than capital. Early investors provide critical validation, open doors to strategic relationships, and help companies build the momentum needed to attract future financing. Understanding how these investors think can give entrepreneurs a significant advantage as they prepare for fundraising.

This panel brings together accomplished investors and innovation leaders who regularly evaluate breakthrough technologies at their earliest stages:

Renaud Jacquemart Omnium Global (Moderator)	Sam Gussman-Toh ARPA-H	William Hsu, PhD NuFund Venture Group
Rohit Jain HBS Alumni Angels of Northern California	Dushyant Pathak Autobahn Labs

These panelists represent a diverse range of perspectives across venture creation, angel investing, government-supported innovation, and early-stage venture capital. Collectively, they helped identify and support companies long before they became widely recognized.

During the discussion, attendees will gain insight into what separates promising startups from investable opportunities. The panel will explore the characteristics investors look for in founding teams, the technical and commercial milestones that inspire confidence, and the common mistakes entrepreneurs make when approaching investors during the earliest stages of fundraising.

The conversation will also address how startups can build credibility before institutional financing, demonstrate meaningful progress with limited resources, and develop fundraising strategies that position them for long-term success.

For founders preparing to raise their first outside capital, this session offers a rare opportunity to hear directly from the investors who are often the first to believe in transformative science and technology.

Whether you are refining your investment story, preparing for investor meetings, or mapping out your fundraising roadmap, The First Believers panel will provide practical insights that can help shape your next steps.

Don’t miss this opportunity to kick off Day 2 of RESI Boston with an inside look at how early-stage investors identify the breakthrough companies of tomorrow.

Build an Investor-Ready Company with Life Science Nation’s Education Program

August 4, 2026August 4, 2026 ~ Next Phase Admin ~ Leave a comment

By Karen Deyo, VP of Product, Israel BD, LSN

Raising capital is more than having innovative science. Early-stage life science companies also need a compelling story, a clear fundraising strategy, and the ability to engage the right investors. Life Science Nation’s (LSN) Education Program helps founders build those skills, preparing them for a successful fundraising campaign that typically spans 9 to 18 months.

Designed for biotechnology, medical device, diagnostics, digital health, and life science tool companies, the program gives entrepreneurs practical guidance while helping accelerators, incubators, universities, and regional innovation organizations better prepare their portfolio companies for investor engagement.

Two Programs, One Goal
Organizations can choose the level of support that best fits their companies’ needs.

Preparing and Executing a RESI Event includes:

Three virtual education sessions
In-person Pitch Practice and Shark Tank before RESI

Preparing and Executing a Global Roadshow includes:

Twelve virtual education sessions
A dedicated LSN mentor with coaching between classes
In-person Pitch Practice and Shark Tank

Throughout the curriculum, founders learn how investors evaluate opportunities, refine their branding and messaging, align fundraising goals with company milestones, and develop a systematic approach to investor outreach. Participants also learn how to navigate the RESI Partnering Platform, identify the right investors, execute productive meetings, and build an effective follow-up strategy after the conference.

The program concludes with an in-person Pitch Practice and Shark Tank held before RESI, giving companies the opportunity to present their technology, receive live feedback, and strengthen their investor presentations before meeting with active investors.

Putting Preparation into Practice

The Education Program is designed to prepare companies for the Redefining Early Stage Investments (RESI) Conference Series, where startups connect with active investors, pharmaceutical companies, strategic partners, and service providers from across the global life science ecosystem.

Companies can further increase their visibility by participating in the Innovator’s Pitch Challenge (IPC). Each company delivers a six-minute presentation followed by seven minutes of investor Q&A, while also showcasing its technology in the RESI Exhibition Hall. IPC participants receive additional exposure through the LSN Newsletter and RESI Program Guide, with audience voting determining the competition winners.

Together, the Education Program, RESI Conference, and Innovator’s Pitch Challenge provide founders with a complete framework for fundraising success—from developing an investor-ready message to building meaningful relationships that can help move their companies forward.

Interested in bringing the Life Science Nation Education Program to your portfolio companies? Visit www.lifesciencenation.com and www.resiconference.com to learn more.